Publications

Biosimilar medicine fact sheet – bevacizumab

This fact sheet provides information about biosimilar brands of bevacizumab listed on the Pharmaceutical Benefits Scheme (PBS).

Mvasi® was listed on the PBS on 1 June 2021 under the Efficient Funding of Chemotherapy arrangements of the Section 100 Highly Specialised Drugs Program.

Biosimilar medicine fact sheet – bevacizumab

About this resource

Publication date:
Publication type:
Fact sheet
Audience:
General public
Language:
English
Part of a collection:
Biosimilar medicines information collection
Tags: 

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.